Dec 14, 2021 7:15 am EST Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
Nov 15, 2021 7:30 am EST Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 8, 2021 7:30 am EST EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy
Oct 26, 2021 7:00 am EDT EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.
Sep 9, 2021 4:15 pm EDT EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 8, 2021 6:55 am EDT EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation
Aug 12, 2021 4:15 pm EDT EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 11, 2021 4:15 pm EDT EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Aug 10, 2021 6:55 am EDT EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jul 26, 2021 4:15 pm EDT EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer